Novo Nordisk A/S: The Acquisition of Catalent by Novo Holdings, and the Related Acquisition by Novo Nordisk of Three Manufacturing Sites From Novo Holdings, Is Cleared to Close
Novo Nordisk A/S: The Acquisition of Catalent by Novo Holdings, and the Related Acquisition by Novo Nordisk of Three Manufacturing Sites From Novo Holdings, Is Cleared to Close
Upon completion, the acquisition is expected to impact the financial outlook as issued on 6 November 2024, with a low single-digit negative impact on operating profit growth and to negatively impact free cash flow with the 11.7 billion USD acquisition price. The ongoing share buyback programme of 20 billion DKK is not impacted.Bagsværd, Denmark, 14 December 2024 — As of today, all regulatory closing conditions relating to the review of Novo Holdings A/S's pending acquisition of Catalent, Inc. (Catalent), including expiry of the timing agreement in the US, have been fulfilled. Catalent is a global contract development and manufacturing organisation headquartered in New Jersey (US). The parties are now free to close the transaction, as well as Novo Nordisk's subsequent acquisition of three Catalent manufacturing sites from Novo Holdings A/S.
丹麥巴格斯瓦德，2024年12月14日——截至今天，與Novo Holdings A/S待購的Catalent, Inc.（Catalent）收購審查相關的所有監管條件，包括美國的時間協議到期，均已滿足。Catalent是一家全球合同開發和製造組織，總部位於美國新澤西州。各方現在可以自由完成交易，以及Novo Nordisk隨後從Novo Holdings A/S收購三家Catalent製造基地的交易。
The agreement to acquire the three manufacturing sites was announced on 5 February 2024. For further information, please see the company announcement here.
收購這三家制造基地的協議於2024年2月5日宣佈。有關更多信息，請查看公司的公告。
Novo Nordisk now expects the acquisition to be completed in the coming days.
Novo Nordisk現在預計收購將在接下來的幾天內完成。
Upon completion, the acquisition is expected to impact the financial outlook as issued on 6 November 2024, with a low single-digit negative impact on operating profit growth and to negatively impact free cash flow with the 11.7 billion USD acquisition price. The ongoing share buyback programme of 20 billion DKK is not impacted.
完成後，預計該收購將對2024年11月6日發佈的財務前景產生影響，營業利潤增長將受到低個位數的負面影響，並將對自由現金流產生負面影響，收購價格爲117億 美元指數。進行中的200億丹麥克朗的股票回購計劃不受影響。
For 2025, the acquisition is expected to have a mid single-digit negative impact on operating profit growth. The acquisition will be mainly debt-financed, with interest payments negatively impacting net financial items. Novo Nordisk's capital allocation priorities focus on internal growth investments, including supply chain expansions, dividends as well as external growth opportunities, including acquiring the three manufacturing sites. Consequently, Novo Nordisk is not expecting to initiate a share buyback programme in 2025.
到2025年，這項收購預計將對營業利潤增長產生中等個位數的負面影響。這項收購主要將通過債務融資，利息支付將對淨財務項目產生負面影響。諾和諾德的資本分配優先考慮內部增長投資，包括供應鏈擴展、分紅派息以及外部增長機會，包括收購這三家制造業-半導體。因而，諾和諾德預計在2025年不會啓動股票回購計劃。
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 72,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
諾和諾德是一家領先的全球醫療保健公司，成立於1923年，總部位於丹麥。我們的目標是推動變革，以擊敗嚴重的慢性疾病，這基於我們在糖尿病領域的傳統。我們通過開創科學突破、擴大藥品的可及性，以及努力預防和最終治癒疾病來實現這一目標。諾和諾德在80個國家僱傭約72,000名員工，並在約170個國家銷售我們的產品。諾和諾德的B類股票在納斯達克哥本哈根上市（Novo-B）。其美國存托股票（ADRs）在紐約證券交易所上市（NVO）。有關更多信息，請訪問novonordisk.com、Facebook、Instagram、X、LinkedIn和YouTube。
Contacts for further information
更多信息的聯繫人
| Media: | |
|
Ambre James-Brown +45 3079 9289 abmo@novonordisk.com |
Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com |
| Investors: | |
|
Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com |
David Heiberg Landsted +45 3077 6915 dhel@novonordisk.com |
|
Sina Meyer +45 3079 6656 azey@novonordisk.com |
Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com |
|
Frederik Taylor Pitter +1 609 613 0568 fptr@novonordisk.com |
| 媒體： | |
| 安佈雷·詹姆斯-布朗 +45 3079 9289 abmo@novonordisk.com |
莉茲·斯克爾博娃（美國） +1 609 917 0632 lzsk@novonordisk.com |
| 投資者： | |
| 雅各布·馬丁·維博格·羅德 +45 3075 5956 jrde@novonordisk.com |
大衛·海伯格·蘭斯特德 +45 3077 6915 dhel@novonordisk.com |
| 西娜·梅耶 +45 3079 6656 azey@novonordisk.com |
伊達·沙普·梅爾沃德 +45 3077 5649 idmg@novonordisk.com |
| 弗雷德裏克·泰勒·皮特 +1 609 613 0568 fptr@novonordisk.com |
Company announcement No 96 / 2024
公司公告第 96 / 2024 號
Attachment
附件
- PR241214-Catalent-clearance-to-close
- PR241214-Catalent-關閉清算
譯文內容由第三人軟體翻譯。